Biotinylated Human Fc epsilon RI alpha Protein, His,Avitag™ (MALS & BLI verified)

用户评价
货号-规格
价格
Qty.
FCA-H82E3-25ug
¥3675.00
FCA-H82E3-200ug
¥15960.00
合计0件 产品金额¥ 0

产品详情

  • 分子别名(Synonym)

    FCER1A,FCE1A,FcERI

  • 表达区间及表达系统(Source)

    Biotinylated Human Fc epsilon RI alpha Protein, His,Avitag (FCA-H82E3) is expressed from human 293 cells (HEK293). It contains AA Val 26 - Gln 205 (Accession # P12319-1).

    Predicted N-terminus: Val 26

    Request for sequence
  • 蛋白结构(Molecular Characterization)

    Fc epsilon RI alpha Structure

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 24.6 kDa. The protein migrates as 50-55 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • 标记(Labeling)

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • 蛋白标记度(Protein Ratio)

    Passed as determined by the HABA assay / binding ELISA.

  • 纯度(Purity)

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • 制剂(Formulation)

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 重构方法(Reconstitution)

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • 存储(Storage)

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

推荐产品

数据展示

  • 电泳(SDS-PAGE)

    Fc epsilon RI alpha SDS-PAGE

    Biotinylated Human Fc epsilon RI alpha Protein, His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    Fc epsilon RI alpha SEC-MALS

    The purity of Biotinylated Human Fc epsilon RI alpha Protein, His,Avitag (Cat. No. FCA-H82E3) is more than 90% and the molecular weight of this protein is around 40-50 kDa verified by SEC-MALS.

    Report
  • 活性(Bioactivity)-ELISA

     Fc epsilon RI alpha ELISA

    Immobilized Human IgE Fc, His Tag (Cat. No. IGE-H52H9) at 1 μg/mL (100 μL/well) can bind Biotinylated Human Fc epsilon RI alpha Protein, His,Avitag (Cat. No. FCA-H82E3) with a linear range of 0.02-0.6 ng/mL (QC tested).

    Protocol
  • 活性(Bioactivity)-BLI

     Fc epsilon RI alpha BLI

    Loaded Biotinylated Human Fc epsilon RI alpha Protein, His,Avitag (Cat. No. FCA-H82E3) on SA Biosensor, can bind Immunoglobulin E, Human Plasma with an affinity constant of 1.92 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

用户评价
发表评论

背景介绍

High affinity immunoglobulin epsilon receptor subunit alpha (FCER1A) is also known as Fc-epsilon RI-alpha (FcERI), IgE Fc receptor subunit alpha, FCE1A. FCER1A contains two Ig-like (immunoglobulin-like) domains. FCER1A binds to the Fc region of immunoglobulins epsilon and is a high affinity receptor. FCER1A is responsible for initiating the allergic response, which binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators (such as histamine) responsible for the manifestations of allergy. The same receptor also induces the secretion of important lymphokines. FCER1A plays a central role in allergic disease, coupling allergen and mast cell to initiate the inflammatory and immediate hypersensitivity responses that are characteristic of disorders such as hay fever and asthma.

前沿进展

 
药物研发进展
  • 英文全称:

    IgE Fc receptor, alpha-subunit

  • 中文全称:

    IgE-Fc片段受体α亚基

  • 种类:

  • 上市药物数量:

    1 详情

  • 临床药物数量:

    0 详情

  • 最高研发阶段:

    批准上市

联系我们
项目合作
查看更多项目
实验案例分析
查看更多案例分析
  • 产品基础信息
  • 产品详情
  • 推荐产品
  • 数据展示
  • 用户评价
  • 背景介绍